Skip to main content

Table 1 Baseline demographic and clinical characteristics of the three patient groups

From: Effect of switching administration of alendronate after teriparatide for the prevention of BMD loss around the implant after total hip arthroplasty, 2-year follow-up: a randomized controlled trial

 SwitchALDControlP value
Number of subjects171516 
Male/female1/161/144/11 
Average age, years65.8 ± 10.663.8 ± 9.364.8 ± 9.2N.S.
Average BMI, kg/m221.9 ± 4.224.0 ± 2.624.6 ± 3.8N.S.
JOA score49.8 ± 9.753.3 ± 14.548.6 ± 11.0N.S.
UCLA activity score4.4 ± 1.25.0 ± 0.94.4 ± 1.4N.S.
HHS56.9 ± 9.954.7 ± 12.549.2 ± 10.6N.S.
Lumbar spine BMD, g/cm20.8 ± 0.20.9 ± 0.10.9 ± 0.1N.S.